Sudarshan Pharma Industries is under due diligence for acquiring a 9.50% stake in MedTherapy Biotechnology. This includes a 1.50% stake from its promoters. The acquisition aims to enhance its US market presence, with completion expected by March 2027.
Sudarshan Pharma Industries is under due diligence for acquiring a 9.50% stake in MedTherapy Biotechnology. This includes a 1.50% stake from its promoters. The acquisition aims to enhance its US market presence, with completion expected by March 2027.
<iframe src="https://hindustansphere.com/embed/cluster/0ddc71163043e15f3ff967947ab3f69eea9c78ad" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="350% rally in 3 years, multibagger pharma stock to be in focus on Wednesday | Key details from filing"></iframe>
